Takeda Pharmaceutical Company Limited TAK
Set alert
At close · Oct 30
After hours · Oct 30, 5:26 PM ET
- YTD
- +34.12%
- 1 year
- +58.05%
- Open
- 21.00
- Prev close
- 20.01
- Mkt cap
- 66.81B
- Vol
- 4.62M
- Avg vol
- 2.73M
- EPS
- 0.07
- P/E
- 298.71
- Div yield
- 3.08%
More statistics
- Low
- 20.80
- High
- 21.22
- Forward P/E
- 39.48
- Beta
- 0.10
- Short ratio
- 1.21
- Inst. own
- 3.32%
- Dividend
- 0.62
- Ex-div date
- Mar 30, 2026
- Earnings
- Jan 28, 2027
- 50-d avg
- 18.78
- 200-d avg
- 17.53
- 1y target
- 23.08
MAX chart
Events in this range
- Oct 7, 2021Downgrade: Morgan Stanley · Overweight → Equal-Weight
- Apr 4, 2023Rating: TD Cowen · — → Outperform
Signals (97)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Jul 1, 2026 | 4 months ago |
| SMA: Bearish | May 1, 2026 | 6 months ago |
| SMA: Bullish | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 1, 2025 | 12 months ago |
| SMA: Bearish | Oct 1, 2025 | 1 year ago |
| SMA: Bearish | Oct 1, 2025 | 1 year ago |
| SMA: Bullish | Aug 1, 2025 | 1 year ago |
| SMA: Bullish | Aug 1, 2025 | 1 year ago |
| SMA: Bearish | Jul 1, 2025 | 1 year ago |
| SMA: Bearish | Jul 1, 2025 | 1 year ago |
| SMA: Bullish | Mar 1, 2025 | 1 year ago |
| SMA: Bullish | Feb 1, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 1, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 1, 2024 | 1 year ago |
| SMA: Bearish | Sep 1, 2024 | 2 years ago |
| SMA: Bullish | Aug 1, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 1, 2024 | 2 years ago |
| SMA: Bullish | Jul 1, 2024 | 2 years ago |
| MACD: Sell Signal | Nov 1, 2023 | 3 years ago |
| SMA: Bearish | Oct 1, 2023 | 3 years ago |
| SMA: Bullish | Aug 1, 2023 | 3 years ago |
| SMA: Bearish | Jul 1, 2023 | 3 years ago |
| SMA: Bearish | Jul 1, 2023 | 3 years ago |
| SMA: Bullish | Mar 1, 2023 | 3 years ago |
| SMA: Bearish | Feb 1, 2023 | 3 years ago |
| SMA: Bullish | Jan 1, 2023 | 3 years ago |
| SMA: Bullish | Nov 1, 2022 | 4 years ago |
| MACD: Buy Signal | Nov 1, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 1, 2022 | 4 years ago |
| SMA: Bearish | Aug 1, 2022 | 4 years ago |
| SMA: Bullish | Jul 1, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 1, 2022 | 4 years ago |
| MACD: Sell Signal | Oct 1, 2021 | 5 years ago |
| SMA: Bearish | Apr 1, 2021 | 5 years ago |
| SMA: Bearish | Apr 1, 2021 | 5 years ago |
| SMA: Bullish | Mar 1, 2021 | 5 years ago |
| SMA: Bullish | Mar 1, 2021 | 5 years ago |
| SMA: Bearish | Jan 1, 2021 | 5 years ago |
| SMA: Bullish | Nov 1, 2020 | 6 years ago |
| SMA: Bearish | Sep 1, 2020 | 6 years ago |
| SMA: Bullish | Aug 1, 2020 | 6 years ago |
| SMA: Bearish | Jun 1, 2020 | 6 years ago |
| SMA: Bullish | Apr 1, 2020 | 6 years ago |
| MACD: Buy Signal | Apr 1, 2020 | 6 years ago |
| MACD: Sell Signal | Mar 1, 2020 | 6 years ago |
| SMA: Bearish | Feb 1, 2020 | 6 years ago |
| SMA: Bullish | Nov 1, 2019 | 7 years ago |
| MACD: Buy Signal | Nov 1, 2019 | 7 years ago |
| SMA: Bearish | Apr 1, 2019 | 7 years ago |
| SMA: Bullish | Mar 1, 2019 | 7 years ago |
| MACD: Sell Signal | Apr 1, 2018 | 8 years ago |
| SMA: Bearish | Mar 1, 2018 | 8 years ago |
| SMA: Bearish | Mar 1, 2018 | 8 years ago |
| MACD: Buy Signal | Mar 1, 2017 | 9 years ago |
| SMA: Bullish | Feb 1, 2017 | 9 years ago |
| SMA: Bullish | Feb 1, 2017 | 9 years ago |
| SMA: Bearish | Oct 1, 2016 | 10 years ago |
| SMA: Bearish | Oct 1, 2016 | 10 years ago |
| SMA: Bullish | Sep 1, 2016 | 10 years ago |
| SMA: Bullish | Sep 1, 2016 | 10 years ago |
| SMA: Bearish | May 1, 2016 | 10 years ago |
| SMA: Bullish | Apr 1, 2016 | 10 years ago |
| SMA: Bearish | Mar 1, 2016 | 10 years ago |
| MACD: Sell Signal | Mar 1, 2016 | 10 years ago |
| SMA: Bearish | Jan 1, 2016 | 10 years ago |
| SMA: Bullish | Dec 1, 2015 | 10 years ago |
| SMA: Bearish | Nov 1, 2015 | 11 years ago |
| SMA: Bullish | Oct 1, 2015 | 11 years ago |
| SMA: Bullish | Oct 1, 2015 | 11 years ago |
| MACD: Buy Signal | Oct 1, 2015 | 11 years ago |
| SMA: Bearish | Sep 1, 2015 | 11 years ago |
| SMA: Bearish | Sep 1, 2015 | 11 years ago |
| MACD: Sell Signal | Sep 1, 2015 | 11 years ago |
| MACD: Buy Signal | Feb 1, 2015 | 11 years ago |
| SMA: Bullish | Jan 1, 2015 | 11 years ago |
| SMA: Bullish | Jan 1, 2015 | 11 years ago |
| SMA: Bearish | Apr 1, 2014 | 12 years ago |
| SMA: Bearish | Apr 1, 2014 | 12 years ago |
| SMA: Bullish | Feb 1, 2014 | 12 years ago |
| SMA: Bullish | Jan 1, 2014 | 12 years ago |
| SMA: Bearish | Dec 1, 2013 | 12 years ago |
| SMA: Bearish | Dec 1, 2013 | 12 years ago |
| SMA: Bullish | Nov 1, 2013 | 13 years ago |
| SMA: Bullish | Sep 1, 2013 | 13 years ago |
| MACD: Sell Signal | Jul 1, 2013 | 13 years ago |
| SMA: Bearish | May 1, 2013 | 13 years ago |
| SMA: Bearish | May 1, 2013 | 13 years ago |
| SMA: Bullish | Jan 1, 2013 | 13 years ago |
| SMA: Bullish | Jan 1, 2013 | 13 years ago |
| SMA: Bearish | Dec 1, 2012 | 13 years ago |
| SMA: Bearish | Nov 1, 2012 | 14 years ago |
| SMA: Bullish | Jun 1, 2012 | 14 years ago |
| SMA: Bearish | Sep 1, 2011 | 15 years ago |
| SMA: Bullish | Jul 1, 2011 | 15 years ago |
| SMA: Bearish | May 1, 2011 | 15 years ago |
| SMA: Bullish | Apr 1, 2011 | 15 years ago |
| SMA: Bearish | Mar 1, 2011 | 15 years ago |
Key statistics
- Market cap
- 66.85B
- Enterprise value
- 5.14T
- Trailing P/E
- 298.93
- Forward P/E
- 39.48
- PEG ratio
- 0.45
- Price / sales
- 0.01
- Price / book
- 1.38
- EPS (TTM)
- 0.07
- Beta
- 0.10
- Dividend yield
- 3.08%
- Payout ratio
- 426.53%
- Profit margin
- -3.54%
- Revenue (TTM)
- 4.62T
- Revenue growth
- 10.20%
- Free cash flow
- 541.44B
- Total cash
- 460.98B
- Total debt
- 5.54T
- Return on equity
- -2.26%
- Shares outstanding
- 3.19B
- Short % of float
- 0.10%
- 50-day average
- 18.78
- 200-day average
- 17.53
Analyst view
Consensus: strong buy
- Target (low)
- 21.04
- Target (mean)
- 23.08
- Target (high)
- 26.06
- Strong buy0
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Jan 28, 2027
Expected Jan 28, 2027. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 28, 2027 | Dec 30, 2026 | 0.2815 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 0.145 | 0.3852 | +0.24 | +165.66% |
| Jul 30, 2026 | Jun 30, 2026 | 0.1689 | 0.225 | +0.06 | +33.21% |
| May 13, 2026 | Mar 31, 2026 | 0.21 | -0.04919 | -0.26 | -123.42% |
| Jan 29, 2026 | Dec 31, 2025 | 0.55 | 0.2131 | -0.34 | -61.25% |
| Oct 30, 2025 | Sep 30, 2025 | 0.44 | -0.02493 | -0.46 | -105.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 16, 2023 | TD Cowen | main | Outperform | Outperform |
| Apr 4, 2023 | TD Cowen | main | — | Outperform |
| Mar 16, 2023 | B of A Securities | up | Neutral | Buy |
| Jul 19, 2022 | Cowen & Co. | up | Market Perform | Outperform |
| Oct 7, 2021 | Morgan Stanley | down | Overweight | Equal-Weight |
| Mar 11, 2020 | JP Morgan | main | — | Overweight |
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Japan
- Website
- takeda.com
News
- Takeda Pharmaceutical's Earnings Growth Has Yet To Translate To Higher Cash Flow
- What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call
- Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang
- Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang
- Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript
- Takeda Pharmaceutical Co Q2 2026 Earnings Call Transcript
- Takeda Pharmaceutical Co Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B
- Takeda Pharmaceutical Q2 Adj. EPS $0.48 Beats $0.31 Estimate, Sales $7.457B Beat $7.190B Estimate
- Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
- Takeda Announces Results From Its Phase 3 G-HOPE-001 Study Of Arcotatug Tavatecan In Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma; Arcotatug Tavatecan Met Dual Primary Endpoints Of Overall Survival And Progression-Free Survival, Showing Significant Improvements
Your note
Sign in to keep a note on TAK — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Capital Research Global Investors | 0.60% | 19,297,680 | 403.80M | Jun 29, 2026 |
| FMR, LLC | 0.30% | 9,599,302 | 200.87M | Jun 29, 2026 |
| Morgan Stanley | 0.22% | 6,994,924 | 146.37M | Jun 29, 2026 |
| Adage Capital Partners GP L.L.C. | 0.19% | 6,050,771 | 126.61M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 0.16% | 5,125,032 | 107.24M | Jun 29, 2026 |
| Brandes Investment Partners L.P. | 0.14% | 4,539,347 | 94.99M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AMERICAN MUTUAL FUND | 0.57% | 18,157,900 | 379.95M | Sep 29, 2026 |
| Capital Income Builder | 0.23% | 7,343,700 | 153.67M | Sep 29, 2026 |
| VanEck ETF Trust-VanEck Pharmaceutical ETF | 0.05% | 1,538,888 | 32.20M | Sep 29, 2026 |
| First TRT Exch-Trd Fd.-First TRT Value Line Dividend Index Fd. | 0.05% | 1,714,201 | 35.87M | Sep 29, 2026 |
| Mercer Funds-Mercer Non-US Core Equity Fund | 0.02% | 586,098 | 12.26M | Jun 29, 2026 |
| GOLDMAN SACHS TRUST-Goldman Sachs Income Builder Fund | 0.02% | 494,442 | 10.35M | Jul 30, 2026 |